Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T20:14:04.138Z.
Calculation as of: 2026-10-06T20:14:04.138Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc3fa1fa429e6ac4f0d7012b2af5cf8e78abb5153a19c38995711b2f102458f4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$438.07M
PB Ratio
11.43
TTM Avg
8.04
3Y Avg
5.21
5Y Avg
3.76
Market Cap
$445.71M
PB Ratio
1.81
TTM Avg
6.76
3Y Avg
9.79
5Y Avg
10.19
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | 11.43 | 8.04 | 5.21 | 3.76 |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | 36.35 | 30.70 | 24.90 | 16.42 |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | 1.44 | 2.81 | 3.05 | 2.11 |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | 2.11 | 1.72 | 1.48 | 1.41 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | 34.09 | 12.79 | 7.49 | 5.62 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 1.81 | 6.76 | 9.79 | 10.19 |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 0.54 | 0.38 | 0.37 | 0.38 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 1.89 | 1.99 | 2.71 | 1.98 |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 0.26 | 0.42 | 0.33 | 0.36 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
